Translations:Sodium/glucose cotransporter 2/4/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 19:48, 18 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Sodium/glucose cotransporter 2)
== SGLT2 inhibitors for diabetes ==
{{Main|SGLT2 inhibitor}}
[[SGLT2 inhibitor]]s are also called gliflozins or flozins. They lead to a reduction in blood glucose levels, and therefore have potential use in the treatment of [[type 2 diabetes]]. Gliflozins enhance glycemic control as well as reduce [[Human body weight|body weight]] and systolic and diastolic [[blood pressure]]. The gliflozins canagliflozin, dapagliflozin, and empagliflozin may lead to euglycemic [[ketoacidosis]]. Other side effects of gliflozins include increased risk of Fournier gangrene

SGLT2 inhibitors for diabetes

Main article: SGLT2 inhibitor

SGLT2 inhibitors are also called gliflozins or flozins. They lead to a reduction in blood glucose levels, and therefore have potential use in the treatment of type 2 diabetes. Gliflozins enhance glycemic control as well as reduce body weight and systolic and diastolic blood pressure. The gliflozins canagliflozin, dapagliflozin, and empagliflozin may lead to euglycemic ketoacidosis. Other side effects of gliflozins include increased risk of Fournier gangrene

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Sodium/glucose_cotransporter_2/4/en&oldid=116848"